Combined General Meeting of June 30, 2026 – Availability of the Preparatory Documents

Key Takeaways:

• Inventiva has scheduled a Combined General Meeting for June 30, 2026.
• Preparatory documents for the event are now accessible.
• The company specializes in oral therapies targeting MASH.
• Inventiva is listed on both Euronext Paris and NASDAQ.
• Timely disclosure demonstrates the company’s dedication to stakeholder engagement.

Corporate Announcement

Inventiva, a clinical-stage biopharmaceutical company, recently announced the availability of preparatory documents for its Combined General Meeting, set for June 30, 2026. The firm, which has offices in Daix (France) and New York City (United States), made this information public on June 9, 2026, to ensure transparency and preparedness among shareholders.

Backdrop on Inventiva

Inventiva is actively working to develop oral therapies for the treatment of metabolic dysfunction-associated steatohepatitis (MASH). Notably listed on Euronext Paris and NASDAQ under the ticker IVA, the company is recognized for its focused approach to addressing global health issues related to metabolic diseases.

Meeting Details

With the release of preparatory documents for the June 30 event, Inventiva aims to keep its investors and stakeholders thoroughly informed. The documents outline the agenda and potential resolutions to be discussed at the meeting, enabling participants to review core topics and engage in meaningful dialogue when they convene.

Focus on MASH Research

MASH, or metabolic dysfunction-associated steatohepatitis, remains a primary concern for many healthcare and pharmaceutical entities worldwide. As a clinical-stage biopharmaceutical company, Inventiva continues to highlight the importance of developing advanced, orally administered therapies that could transform how this widespread condition is addressed.

Final Observations

The public release of these materials underscores Inventiva’s broader commitment to stakeholder communication and collaboration. By granting early access to documentation, the company prioritizes transparency and fosters an environment of preparedness. With the June 30 Combined General Meeting fast approaching, both shareholders and analysts are encouraged to review these materials for the latest insights into Inventiva’s plans and strategic direction.